Beijing SL Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Beijing SL Pharmaceutical Co., Ltd. carries a market capitalization of 6.11B, placing it among publicly traded companies globally. Its enterprise value stands at 7.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.11B |
| Enterprise Value | 7.27B |
Share Statistics
Beijing SL Pharmaceutical Co., Ltd. currently has 1.03B shares outstanding.
| Shares Outstanding | 1.03B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Beijing SL Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 468.47. The price-to-sales ratio is 14.21, and the price-to-book ratio stands at 1.63.
| PE Ratio | 468.47 |
| PS Ratio | 14.21 |
| PB Ratio | 1.63 |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | 19.86 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 12.68 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 17.72 |
Financial Position
Beijing SL Pharmaceutical Co., Ltd. maintains a current ratio of 12.79, meaning it holds 12.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.79 |
| Quick Ratio | 4.43 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | 0.34 |
| Return on Assets (ROA) | 0.29 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -1.56 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.79 |
Taxes
Over the trailing twelve months, Beijing SL Pharmaceutical Co., Ltd. has paid -32.52M in income taxes, reflecting an effective tax rate of 20.01.
| Income Tax | -32.52M |
| Effective Tax Rate | 20.01 |
Stock Price Statistics
Beijing SL Pharmaceutical Co., Ltd.'s stock has declined approximately -19.04762% over the past 52 weeks. The 50-day moving average sits at 5.99, while the 200-day moving average is 6.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | -19.04762% |
| 50-Day Moving Average | 5.99 |
| 200-Day Moving Average | 6.95 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Beijing SL Pharmaceutical Co., Ltd. generated 573.22M in revenue and converted that into 17.39M in net income, yielding earnings per share of 0.01. EBITDA reached -71.18M, while operating income came in at -71.18M.
| Revenue | 573.22M |
| Gross Profit | 337.94M |
| Operating Income | -71.18M |
| Pretax Income | -15.97M |
| Net Income | 17.39M |
| EBITDA | -71.18M |
| EBIT | -71.18M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
Total book value stands at 5.00B, with working capital of 2.36B providing operational flexibility.
| Cash & Cash Equivalents | 886.94M |
| Total Debt | N/A |
| Net Debt | -346.30M |
| Equity (Book Value) | 5.00B |
| Book Value Per Share | 4.35 |
| Working Capital | 2.36B |
Cash Flow
After subtracting -410.27M in capital expenditures, free cash flow totaled -410.27M - equivalent to -0.36 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -410.27M |
| Free Cash Flow | -410.27M |
| FCF Per Share | -0.36 |
Margins
Beijing SL Pharmaceutical Co., Ltd. operates with a gross margin of 58.96, reflecting its pricing power and cost economics. The operating margin of -12.42 and net profit margin of 3.03 provide insight into operational efficiency.
| Gross Margin | 58.96 |
| Operating Margin | -12.42 |
| Pretax Margin | -2.79 |
| Profit Margin | 3.03 |
| EBITDA Margin | -12.42 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | 5.04 |
Stock Splits
Beijing SL Pharmaceutical Co., Ltd.'s most recent stock split took place on July 4, 2019 with a 2:3 split ratio.
| Last Split Date | 7/4/2019 |
| Split Ratio | 2:3 |
Scores
Beijing SL Pharmaceutical Co., Ltd. posts an Altman Z-Score of 17.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 17.25 |